Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and growth requirements, and those differences determine which questions each cell line can answer. Methods Derivation reports, repository entries and subsequent characterization studies were retrieved for each human prostate cell line in current use. Sources were identified by database searching and from the reference lists of earlier reviews, and the primary derivation report was used in preference to any secondary description. Where two sources report a characteristic differently, both are given together with the assay used in each. Results The lines are described grouped by tissue compartment and androgen receptor status rather than by date of derivation, and for each line the derivation, molecular and cytogenetic characteristics, culture requirements, behavior in vivo and documented limitations are set out. Reports that conflict with one another, including the androgen receptor status of PNT1A, WPMY‐1, BPH‐1 and DU145 and the Bax status of DU145, are largely explained by differences in assay sensitivity. Developments since the last comprehensive reviews are covered, including patient‐derived organoid culture, the recombinant origin of the retrovirus reported in 22Rv1, the reassignment of NCI‐H660 to a prostatic origin, and the adoption of short tandem repeat profiling as a condition of publication. Lines derived from men of African ancestry, the xenograft‐maintained lines that are not adapted to plastic, and the in vivo systems used where an intact host is required are included. Conclusions Several descriptions repeated in the secondary literature are not supported by the primary characterization of the lines concerned. Selection of a line from the research question rather than from availability, verification of the relevant target in the working stock, authentication by short tandem repeat profiling, and full reporting of passage number and culture conditions would remove a substantial part of the variability presently seen in this literature.

Authors

Institutions

Publication Details

Journal
The Prostate
Published
2026-10-06
DOI
https://doi.org/10.1002/pros.70248
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

Keenau Pearce, Hamza Abohamra
The Prostate
Prostate Cancer Treatment and Research
article

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

Keenau Pearce, Hamza Abohamra
article en

Abstract

ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and growth requirements, and those differences determine which questions each cell line can answer. Methods Derivation reports, repository entries and subsequent characterization studies were retrieved for each human prostate cell line in current use. Sources were identified by database searching and from the reference lists of earlier reviews, and the primary derivation report was used in preference to any secondary description. Where two sources report a characteristic differently, both are given together with the assay used in each. Results The lines are described grouped by tissue compartment and androgen receptor status rather than by date of derivation, and for each line the derivation, molecular and cytogenetic characteristics, culture requirements, behavior in vivo and documented limitations are set out. Reports that conflict with one another, including the androgen receptor status of PNT1A, WPMY‐1, BPH‐1 and DU145 and the Bax status of DU145, are largely explained by differences in assay sensitivity. Developments since the last comprehensive reviews are covered, including patient‐derived organoid culture, the recombinant origin of the retrovirus reported in 22Rv1, the reassignment of NCI‐H660 to a prostatic origin, and the adoption of short tandem repeat profiling as a condition of publication. Lines derived from men of African ancestry, the xenograft‐maintained lines that are not adapted to plastic, and the in vivo systems used where an intact host is required are included. Conclusions Several descriptions repeated in the secondary literature are not supported by the primary characterization of the lines concerned. Selection of a line from the research question rather than from availability, verification of the relevant target in the working stock, authentication by short tandem repeat profiling, and full reporting of passage number and culture conditions would remove a substantial part of the variability presently seen in this literature.

The Prostate
University of the Western Cape (ZA)
Openalex Percentile: Top 11%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.